Connection

Co-Authors

This is a "connection" page, showing publications co-authored by HEATH SKINNER and CURTIS R PICKERING.
Connection Strength

2.197
  1. Th2 Cells Are Associated with Tumor Recurrence Following Radiation. Cancers (Basel). 2024 Apr 20; 16(8).
    View in: PubMed
    Score: 0.240
  2. FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner. Clin Cancer Res. 2024 01 05; 30(1):187-197.
    View in: PubMed
    Score: 0.235
  3. p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade. Cancer Res. 2022 03 01; 82(5):916-928.
    View in: PubMed
    Score: 0.207
  4. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun. 2021 11 03; 12(1):6340.
    View in: PubMed
    Score: 0.202
  5. Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis. JCI Insight. 2020 12 03; 5(23).
    View in: PubMed
    Score: 0.190
  6. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Int J Radiat Biol. 2021; 97(8):1121-1128.
    View in: PubMed
    Score: 0.180
  7. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight. 2019 Jan 10; 4(1).
    View in: PubMed
    Score: 0.166
  8. Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. Clin Cancer Res. 2019 03 01; 25(5):1441-1442.
    View in: PubMed
    Score: 0.164
  9. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clin Cancer Res. 2017 Jun 01; 23(11):2713-2722.
    View in: PubMed
    Score: 0.148
  10. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clin Cancer Res. 2016 Sep 15; 22(18):4643-50.
    View in: PubMed
    Score: 0.137
  11. Down-regulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy-induced senescence. Head Neck. 2016 04; 38 Suppl 1:E934-40.
    View in: PubMed
    Score: 0.131
  12. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst. 2022 12 08; 114(12):1619-1627.
    View in: PubMed
    Score: 0.055
  13. High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma. Front Cell Dev Biol. 2022; 10:936168.
    View in: PubMed
    Score: 0.053
  14. Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res. 2015 Apr 01; 75(7):1205-15.
    View in: PubMed
    Score: 0.032
  15. Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Res. 2015 Apr 01; 75(7):1527-36.
    View in: PubMed
    Score: 0.032
  16. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer. 2012 Feb 01; 118(3):711-21.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.